Antithrombotic recombinant antibodies;Anticorps recombinants antithrombotiques

Journal de la Societe de Biologie

Volumn 200, Issue 4, 2006, Pages 365-375

  Muzard, Julien ^a,b   Loyau, Stéphane ^a   Ajzenberg, Nadine ^a   Billiald, Philippe ^b   Jandrot Perrus, Martine ^a  

^a BICHAT HOSPITAL   (France)

^b Museum d'Histoire Naturalle   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; RECOMBINANT PROTEIN; VON WILLEBRAND FACTOR;

CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; IMMUNOLOGY; PROTEIN CONFORMATION; REVIEW; SYNTHESIS;

ANTIBODIES; ANTITHROMBINS; HUMANS; MODELS, MOLECULAR; PLATELET AGGREGATION INHIBITORS; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; VON WILLEBRAND FACTOR;

EID: 34547630311     PISSN: 12950661     EISSN: None     Source Type: Journal    
DOI: 10.1051/jbio:2006040     Document Type: Review

References (61)

1. Bennett J. S., Structure & function of the platelet integrin αIIbβ3. J. Clin. Invest. 2005, 115, 3363-3369.
2. Berlanga O., Tulasne D., Bori T., Snell D.C., Miura Y., Jung S., Moroi M., Frampton J. & Watson S. P., The Fc receptor γ-chain is necessary and sufficient to initiate signalling through glycoprotein VI in transfected cells by the snake C- type lectin, convulxin. Eur. J. Biochem., 2002, 269, 2951-2960.
3. Boylan B., Berndt M. C., Kahn M. L. & Newman P. J., Activation-independent, antibody-mediated removal of GPVI from circulating human platelets: development of a novel NOD/SCID mouse model to evaluate the in vivo effectiveness of anti-human platelet agents. Blood, 2006, 108, 908-914.
4. Boylan B., Chen H., Rathore V., Paddock C., Salacz M., Friedman K. D., Curtis B. R., Stapleton M., Newman D. K., Kahn M. L. & Newman P. J., Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRγ-chain complex from the human platelet surface. Blood, 2004, 104, 1350-1355.
5. Cadroy Y., Hanson S. R., Kelly A. B., Marzec U. M., Evatt B. L., Kunicki T. J., Montgomery R. R. & Harker L. A., Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. Blood, 1994, 83, 3218-3224.
6. Cauwenberghs N., Meiring M., Vauterin S., van Wyk V., Lamprecht S., Roodt J. P., Novak L., Harsfalvi J., Deckmyn H. & Kotze H. F., Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in non-human primates. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 1347-1353.
7. Cauwenberghs N., Vanhoorelbeke K., Vauterin S. & Deckmyn H., Structural determinants within platelet glycoprotein Ibα involved in its binding to von Willebrand factor. Platelets, 2000, 11, 373-378.
8. Cauwenberghs N., Vanhoorelbeke K., Vauterin S., Westra D. F., Romo G., Huizinga E. G., Lopez J. A., Berndt M. C., Harsfalvi J. & Deckmyn H., Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibα reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibα. Blood, 2001, 98, 652-660.
9. Christopoulos C. G., Thrombocytopenia following treatment with platelet glycoprotein IIb/IIIa inhibitors. Blood, 2003, 101, 1655; author reply 1655.
10. Clemetson J. M., Polgar J., Magnenat E., Wells T. N. & Clemetson K. J., The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcαR and the natural killer receptors. J. Biol. Chem., 1999, 274, 29019-29024.
11. Coller B. S., Folts J. D., Scudder L. E. & Smith S. R., Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood, 1986, 68, 783-786.
12. Coller B. S., Folts J. D., Smith S. R., Scudder L. E. & Jordan R., Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation, 1989, 80, 1766-7174.
13. Coller B. S., Peerschke E. I., Scudder L. E. & Sullivan C. A., A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J. Clin. Invest., 1983, 72, 325-338.
14. Cosemans J. M., Kuijpers M. J., Lecut C., Loubele S. T., Heeneman S., Jandrot-Perrus M. & Heemskerk J. W., Contribution of platelet glycoprotein VI to the thrombogenic effect of collagens in fibrous atherosclerotic lesions. Atherosclerosis, 2005, 181, 19-27.
15. Curtis B. R., Swyers J., Divgi A., McFarland J. G. & Aster R. H., Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood, 2002, 99, 2054-2059.
16. De Luca G., Suryapranata H., Stone G. W., Antoniucci D., Tcheng J. E., Neumann F. J., Van de Werf F., Antman E. M. & Topol E. J., Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA, 2005, 293, 1759-1765.
17. Dumont B., Minullina I., Loyau S., Monteiro R. C., Lacapere J. J., Arocas V. & Jandrot-Perrus M., Chimeric Fc Receptors identify ligand binding regions in human glycoprotein VI. J. Mol. Biol., 2006, 361, 877-887.
18. Fontayne A., Vanhoorelbeke K., Pareyn I., Van Rompaey I., Meiring M., Lamprecht S., Roodt J., Desmet J. & Deckmyn H., Rational humanization of the powerful antithrombotic anti-GPIbα antibody: 6B4. Thromb. Haemost., 2006, 96, 671-684.
19. Gils A., Ceresa E., Macovei A. M., Marx P. F., Peeters M., Compernolle G. & Declerck P. J., Modulation of TAFI function through different pathways - implications for the development of TAFI inhibitors. J. Thromb. Haemost., 2005, 3, 2745-2753.
20. Gold H. K., Coller B. S., Yasuda T., Saito T., Fallon J. T., Guerrero J. L., Leinbach R. C., Ziskind A. A. & Collen D., Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation, 1988, 77, 670-677.
21. Gruner S., Prostredna M., Koch M., Miura Y., Schulte V., Jung S. M., Moroi M. & Nieswandt B., Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice. Blood, 2005, 105, 1492-1499.
22. Hanson S. R., Pareti F. I., Ruggeri Z. M., Marzec U. M., Kunicki T. J., Montgomery R. R., Zimmerman T. S. & Harker L. A., Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon. J. Clin. Invest., 1988, 81, 149-158.
23. Harder S., Kirchmaier C. M., Krzywanek H. J., Westrup D., Bae J. W. & Breddin H. K., Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects. Circulation, 1999, 100, 1175-1181.
24. Hodivala-Dilke K. M., McHugh K. P., Tsakiris D. A., Rayburn H., Crowley D., Ullman-Cullere M., Ross F. P., Coller B. S., Teitelbaum S. & Hynes R. O., β3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J. Clin. Invest., 1999, 103, 229-238.
25. Holtkotter O., Nieswandt B., Smyth N., Muller W., Hafner M., Schulte V., Krieg T. & Eckes B., Integrin α2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. J. Biol. Chem., 2002, 277, 10789-10794.
26. Hoylaerts M. F., Yamamoto H., Nuyts K., Vreys I., Deckmyn H. & Vermylen J., von Willebrand factor binds to native collagen VI primarily via its A1 domain. Biochem. J., 1997, 324 (Pt 1), 185-191.
27. Hughes D. L., Stafford P., Hamaia S. W., Harmer J., School-meester A., Deckmyn H., Farndale R. W., Ouwehand W. H. & Watkins N. A., Platelet integrin α2 I-domain specific antibodies produced via domain specific DNA vaccination combined with variable gene phage display. Thromb. Haemost., 2005, 94, 1318-1326.
28. Jandrot-Perrus M., Busfield S., Lagrue A. H., Xiong X., Debili N., Chickering T., Le Couedic J. P., Goodearl A., Dussault B., Fraser C., Vainchenker W. & Villeval J. L., Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily. Blood, 2000, 96, 1798-1807.
29. Kageyama S., Matsushita J. & Yamamoto H., Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis. Eur. J. Pharmacol., 2002, 443, 143-149.
30. Kageyama S., Yamamoto H., Nagano M., Arisaka H., Kayahara T. & Yoshimoto R., Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Br. J. Pharmacol., 1997, 122, 165-171.
31. Kam P. C. & Egan M. K., Platelet glycoprotein IIb/IIIa antagonists: pharmacology and clinical developments. Anesthesiology 2002, 96, 1237-1249.
32. Kastrati A., Mehilli J., Neumann F. J., Dotzer F., ten Berg J., Bollwein H., Graf I., Ibrahim M., Pache J., Seyfarth M., Schuhlen H., Dirschinger J., Berger P. B. & Schomig A., Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA, 2006, 295, 1531-1538.
33. Kato K., Kanaji T., Russell S., Kunicki T. J., Furihata K., Kanaji S., Marchese P., Reininger A., Ruggeri Z.M. & Ware J., The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood, 2003, 102, 1701-1707.
34. Konishi H., Katoh Y., Takaya N., Kashiwakura Y., Itoh S., Ra C. & Daida H., Platelets activated by collagen through immunoreceptor tyrosine-based activation motif play pivotal role in initiation and generation of neointimal hyperplasia after vascular injury. Circulation, 2002, 105, 912-916.
35. Konstantinides S., Ware J., Marchese P., Almus-Jacobs F., Loskutoff D. J. & Ruggeri Z. M., Distinct antithrombotic consequences of platelet glycoprotein Ibα and VI deficiency in a mouse model of arterial thrombosis. J. Thromb. Haemost., 2006, 4, 2014-2021.
36. Krupski W. C., Bass A., Kelly A. B., Ruggeri Z. M., Harker L. A. & Hanson S. R., Interruption of vascular thrombosis by bolus anti-platelet glycoprotein IIb/IIIa monoclonal antibodies in baboons. J. Vasc. Surg., 1993, 17, 294-303; discussion 303-304.
37. Lagrue-Lak-Hal A. H., Debili N., Kingbury G., Lecut C., Le Couedic J. P., Villeval J. L., Jandrot-Perrus M. & Vainchenker W., Expression and function of the collagen receptor GPVI during megakaryocyte maturation. J. Biol. Chem., 2001, 276, 15316-15325.
38. Lecut C., Feeney L. A., Kingsbury G., Hopkins J., Lanza F., Gachet C., Villeval J. L. & Jandrot-Perrus M., Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived Fab fragments. J. Thromb. Haemost., 2003, 1, 2653-2662.
39. Lecut C., Feijge M. A., Cosemans J. M., Jandrot-Perrus M. & Heemskerk J. W., Fibrillar type I collagens enhance platelet-dependent thrombin generation via glycoprotein VI with direct support of α2β1 but not αIIbβ3 integrin. Thromb. Haemost., 2005, 94, 107-114.
40. Lecut C., Schoolmeester A., Kuijpers M.J., Broers J.L., van Zandvoort M. A., Vanhoorelbeke K., Deckmyn H., Jandrot-Perrus M. & Heemskerk J. W., Principal role of glycoprotein VI in α2β1 and αIIbβ3 activation during collagen-induced thrombus formation. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 1727-1733.
41. Lopez J. A., Andrews R. K., Afshar-Kharghan V. & Berndt M. C., Bernard-Soulier syndrome. Blood, 1998, 91, 4397-4418.
42. Mangin P., Yap C. L., Nonne C., Sturgeon S. A., Goncalves I., Yuan Y., Schoenwaelder S. M., Wright C. E., Lanza F. & Jackson S. P., Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRγ deficiency. Blood, 2006, 107, 4346-4353.
43. Massberg S., Konrad I., Bultmann A., Schulz C., Munch G., Peluso M., Lorenz M., Schneider S., Besta F., Muller I., Hu B., Langer H., Kremmer E., Rudelius M., Heinzmann U., Ungerer M. & Gawaz M., Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J. 2004, 18, 397-399.
44. Matsumoto Y., Takizawa H., Gong X., Le S., Lockyer S., Okuyama K., Tanaka M., Yoshitake M., Tandon N.N. & Kambayashi J., Highly potent anti-human GPVI monoclonal antibodies derived from GPVI knockout mouse immunization. Thromb. Res., 2006, 119, 319-329.
45. Matsumoto Y., Takizawa H., Nakama K., Gong X., Yamada Y., Tandon N. N. & Kambayashi J., Ex vivo evaluation of anti-GPVI antibody in cynomolgus monkeys: dissociation between anti-platelet aggregatory effect and bleeding time. Thromb. Haemost., 2006, 96, 167-175.
46. Mazurov A. V., Pevzner D. V., Antonova O. A., Byzova T. V., Khaspekova S. G., Semenov A. V., Vlasik T. N., Samko A. N., Staroverov I. I. & Ruda M. Y., Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty. Platelets, 2002, 13, 465-477.
47. Nieswandt B., Schulte V., Bergmeier W., Mokhtari-Nejad R., Rackebrandt K., Cazenave J. P., Ohlmann P., Gachet C. & Zirngibl H., Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J. Exp. Med., 2001, 193, 459-469.
48. Nurden A. T., Glanzmann thrombasthenia. Orphanet. J. Rare Dis., 2006, 1, 10.
49. Penz S., Reininger A. J., Brandl R., Goyal P., Rabie T., Bernlochner I., Rother E., Goetz C., Engelmann B., Smethurst P. A., Ouwehand W. H., Farndale R., Nieswandt B. & Siess W., Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. FASEB J., 2005, 19, 898-909.
50. Ribba A. S., Loisel I., Lavergne J. M., Juhan-Vague I., Obert B., Cherel G., Meyer D. & Girma J .P., Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb. Haemost., 2001, 86, 848-854.
51. Ruggeri Z. M., Pathogenesis and classification of von Willebrand disease. Haemostasis, 1994, 24, 265-275.
52. Santoro S. A., Identification of a 160,000 dalton platelet membrane protein that mediates the initial divalent cation-dependent adhesion of platelets to collagen. Cell, 1986, 46, 913-920.
53. Schulte V., Reusch H .P., Pozgajova M., Varga-Szabo D., Gachet C. & Nieswandt B., Two-phase antithrombotic protection after anti-glycoprotein VI treatment in mice. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 1640-1647.
54. Siljander P. R., Munnix I. C., Smethurst P. A., Deckmyn H., Lindhout T., Ouwehand W. H., Farndale R. W. & Heemskerk J. W., Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. Blood, 2004, 103, 1333-1341.
55. Smyth S. S., Reis E. D., Vaananen H., Zhang W. & Coller B. S., Variable protection of β3-integrin-deficient mice from thrombosis initiated by different mechanisms. Blood, 2001, 98, 1055-1062.
56. Staelens S., Desmet J., Ngo T.H., Vauterin S., Pareyn I., Barbeaux P., Van Rompaey I., Stassen J. M., Deckmyn H. & Vanhoorelbeke K., Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains. Mol. Immunol., 2006, 43, 1243-1257.
57. Sugiyama T., Okuma M., Ushikubi F., Sensaki S., Kanaji K. & Uchino H., A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. Blood, 1987, 69, 1712-1720.
58. Takaya N., Katoh Y., Iwabuchi K., Hayashi I., Konishi H., Itoh S., Okumura K., Ra C., Nagaoka I. & Daida H., Platelets activated by collagen through the immunoreceptor tyrosine-based activation motif in the Fc receptor γ-chain play a pivotal role in the development of myocardial ischemia-reperfusion injury. J. Mol. Cell. Cardiol., 2005, 39, 856-864.
59. Tcheng J. E., Ellis S. G., George B. S., Kereiakes D. J., Kleiman N. S., Talley J. D., Wang A. L., Weisman H. F., Califf R. M. & Topol E. J., Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation, 1994, 90, 1757-1764.
60. Toomey J. R., Blackburn M. N., Storer B. L., Valocik R. E., Koster P. F. & Feuerstein G. Z., Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosis. Thromb. Res., 2000, 100, 73-79.
61. Wu D., Meiring M., Kotze H. F., Deckmyn H. & Cauwenberghs N., Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 323-328.